Jim Cramer says the best is yet to come at Oracle — plus, his thoughts on 4 more stocks

  • 📰 CNBC
  • ⏱ Reading Time:
  • 22 sec. here
  • 24 min. at publisher
  • 📊 Quality Score:
  • News: 89%
  • Publisher: 72%

Media Noticias

Health Care Industry,Pharmaceuticals,Retail Industry

Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio.

Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. Oracle : The tech giant had a mixed quarter. But it announced new artificial intelligence partnerships with Alphabet 's Google and Microsoft -backed OpenAI. Oracle also reported strong RPO, short for remaining performance obligation. RPO is what contracted customers are expected to pay in the future and the backlog of business.

"This is a momentum stock so it's not necessarily going to give up the ghost here," Cramer said. "But it is expensive versus its cohorts." Johnson & Johnson : The company reached a $700 million settlement with states over the marketing of its talc-based baby powder. This is a positive, Cramer said. But he added that J & J is a health-care staple stock and it's not going to run here.

 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 12. in MX

México Últimas Noticias, México Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030AstraZeneca CEO Pascal Soriot discussed his company’s ambitious revenue goal with CNBC’s Jim Cramer.
Fuente: NBCNewYork - 🏆 270. / 63 Leer más »